6 recruiting. 3 Phase 2, 3 Phase 3.
By phase and status
Follow Elritercept: new trials by email Literature Review of Elritercept trials Research Report on Elritercept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib Placebo, Elritercept - Myelofibrosis, Anemia Phase 3 Recruiting 324 2026-09-10 2026-10-01 A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions Elritercept, Epoetin Alfa - Myelodysplastic Syndrome, Anemia Phase 3 Recruiting 300 2026-05-21 2026-10-19 A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes TAK-226 - Myelodysplastic Syndromes Phase 2 Recruiting 42 2026-04-22 2026-10-28 A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions Elritercept, Placebo - Myelodysplastic Syndromes Phase 3 Recruiting 225 2025-05-06 2026-10-23 A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis Elritercept, Ruxolitinib - Myelofibrosis Phase 2 Recruiting 135 2021-12-16 2026-02-05 A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Elritercept - Myelodysplastic Syndromes, Cytopenia Phase 2 Recruiting 210 2020-08-19 2026-10-19
Conditions studied Anemia (4) · Myelodysplastic Syndromes (4) · Primary Myelofibrosis (2) · Cytopenia (1) · Thrombocytopenia (1)
Sponsors Takeda (6)
Countries Australia (5) · France (5) · Spain (5) · Brazil (4) · Germany (4) · Italy (4) · South Korea (4) · United Kingdom (4) · United States (4) · Bulgaria (3) · Czechia (3) · Hungary (3) · India (3) · Ireland (3) · Israel (3)
NIH funding 2023 (2) , 2025 (1)